What can we learn from brain autopsies in COVID-19?

被引:105
|
作者
Mukerji, Shibani S. [1 ]
Solomon, Isaac H. [2 ]
机构
[1] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02115 USA
[2] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
基金
美国国家卫生研究院;
关键词
COVID-19; SARS-CoV-2; Brain autopsies; Neuropathology; Neuropathogenesis; Immunohistochemistry; Reverse transcriptase polymerase chain reaction;
D O I
10.1016/j.neulet.2020.135528
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19) for which there have been over 50 million confirmed cases and 1.2 million deaths globally. While many SARS-CoV-2 infected individuals are asymptomatic or experience respiratory symptoms, extrapulmonary manifestations, including neurological symptoms and conditions, are increasingly recognized. There remains no clear understanding of the mechanisms that underlie neurological symptoms in COVID-19 and whether SARS-CoV-2 has the potential for neuroinvasion in humans. In this minireview, we discuss what is known from human autopsies in fatal COVID-19, including highlighting studies that investigate for the presence of SARS-CoV-2 in brain and olfactory tissue, and summarize the neuropathological consequences of infection. Incorporating microscopic and molecular findings from brain tissue into what we know about clinical disease will inform best practice management guidance and direct research priorities as it relates to neurological morbidity from COVID-19.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] The effect of COVID-19 on emergency department imaging: what can we learn?
    Sharperson, Camara
    Hanna, Tarek N.
    Herr, Keith D.
    Zygmont, Matthew E.
    Gerard, Roger L.
    Johnson, Jamlik-Omari
    EMERGENCY RADIOLOGY, 2021, 28 (02) : 339 - 347
  • [22] In the face of the future, what do we learn from COVID-19?
    EL-Arabey, Amr Ahmed
    Abdalla, Mohnad
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (11) : 4119 - 4120
  • [23] Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses?
    Ali Hamady
    JinJu Lee
    Zuzanna A. Loboda
    Infection, 2022, 50 : 11 - 25
  • [24] Rapid Testing of Healthcare Employees for COVID-19: What Can We Learn From the Seattle Experience?
    Bryant, Kristina A.
    Isaacs, Pam
    CLINICAL INFECTIOUS DISEASES, 2020, 71 (10) : 2708 - 2709
  • [25] Anticipating human resilience and vulnerability on the path to 2030: What can we learn from COVID-19
    Armenia, Stefano
    Arquitt, Steven
    Pedercini, Matteo
    Pompei, Alessandro
    FUTURES, 2022, 139
  • [26] Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses?
    Hamady, Ali
    Lee, JinJu
    Loboda, Zuzanna A.
    INFECTION, 2022, 50 (01) : 11 - 25
  • [27] COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?
    Sarzi-Puttini, P.
    Giorgi, V.
    Sirotti, S.
    Marotto, D.
    Ardizzone, S.
    Rizzardini, G.
    Antinori, S.
    Galli, M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2020, 38 (02) : 337 - 342
  • [28] What can we learn from COVID-19 to improve opioid treatment? Expert providers respond
    Harris, Lesley M.
    Marsh, Jeanne C.
    Khachikian, Tenie
    Serrett, Veronica
    Kong, Yinfei
    Guerrero, Erick G.
    JOURNAL OF SUBSTANCE USE & ADDICTION TREATMENT, 2023, 154
  • [30] COVID-19 Pandemic: What Can the West Learn From the East?
    Shokoohi, Mostafa
    Osooli, Mehdi
    Stranges, Saverio
    INTERNATIONAL JOURNAL OF HEALTH POLICY AND MANAGEMENT, 2020, 9 (10) : 436 - 438